A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations

Antiviral Research

Volumn 79, Issue 3, 2008, Pages 143-165

  Pinheiro, Eloan dos Santos ^a   Antunes, Octavio Augusto Ceva ^a   Fortunak, Joseph M D ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Atazanavir; Drugs; Efavirenz; Emtricitabine; FTC; HIV 1; Kaletra; Lopinavir; Prices; Ritonavir; Second line; Synthesis; TDF; Tenofovir Disoproxil Fumarate

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NUCLEOTIDE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VIRUS FUSION PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

APIS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 47049098041     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.001     Document Type: Review

References (161)

1. Adamo I., Benedetti F., Berti F., and Campaner P. Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core. Org. Lett. 8 (2006) 51-54
2. Allen, M.S., 1999. Process for the preparation of 5-hydroxymethylthiazoles. US Patent 5,959,118.
3. Anon. Emtricitabine/tenofovir disoproxil fumarate. Drugs R. D. 5 (2004) 160-161
4. Agrofoglio L.A., Amblard F., Nolan S.P., Charamon S., Gillaizeau I., Zevaco T.A., and Guenot P. Synthesis of l-cyclopentenyl nucleosides using ring-closing metathesis and palladium-mediated allylic alkylation methodologies. Tetrahedron 60 (2004) 8397-8404
5. Ali N.M., McKillop A., Mitchell M.B., Rebelo R.A., and Wallbank P.J. Palladium catalyzed cross-coupling reactions of arylboronic acids with π-deficient heteroaryl chlorides. Tetrahedron 48 (1992) 8117-8126
6. Amblard F., Nolan S.P., Schinazi R.F., and Agrofoglio L.A. Efficient synthesis of various acycloalkenyl derivatives of pyrimidine using cross-metathesis and Pd(0) methodologies. Tetrahedron 61 (2005) 537-544
7. Antunes O.A.C. Inibidores da HIV-1 Protease: Uma Revisão. Rev. Bras. Farm 77 (1996) 164-172
8. Arimilli M.N., Kim C.U., Dougherty J., Mulato A., Oliyai R., Shaw J.P., Cundy K.C., and Bischofberger N. Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)-propyl]adenine (PMA). Antivir. Chem. Chemother. 8 (1997) 557-564
9. Arimilli, M.N., Cundy, K.C., Dougherty, J.P., Kim, C.U., Oliyai, R., Stella, V.J., 1999. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability. US Patent 5,922,695.
10. Asami M., Takahashi J., and Inoue S. An asymmetric synthesis of (-)-carbovir. Tetrahedron: Asymm. 5 (1994) 1649-1652
11. Balzarini J., Holý A., Jindrich J., Naesens L., Snoeck R., Schols D., and De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37 (1993) 332-338
12. Balzarini J., Aquaro S., Perno C.F., Witvrouw M., Holý A., and De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219 (1996) 337-341
13. N2 cyclization to oxazolidinones. Tetrahedron Lett. 41 (2000) 10071-10074
14. Benedetti F., and Norbedo S. Epoxyalcohol route to hydroxyethylene dipeptide isosteres: a new synthesis of the diaminoalcohol core of HIV-protease inhibitor ABT-538 (Ritonavir). J. Chem. Soc. Chem. Commun. (2001) 203-204
15. Benedetti F., Berti F., and Norbedo S. Epoxyalcohol route to hydroxyethylene dipeptide isosteres Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer. J. Org. Chem. 67 (2002) 8635-8643
16. Benzaria S., Pélicano H., Johnson R., Maury G., Imbach J.L., Aubertin A.M., Obert G., and Gosselin G. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J. Med. Chem. 39 (1996) 4958-4965
17. Bergmeier S.C., and Stanchina D.M. Acylnitrene route to vicinal amino alcohols Application to the synthesis of (-)-bestatin and analogues. J. Org. Chem. 64 (1999) 2852-2859
18. Berranger T., and Langlois Y. [2 + 3]-Cycloadditions of enantiomerically pure oxazoline-N-oxides 1: a short stereoselective synthesis of (+)-carbovir. Tetrahedron Lett. 36 (1995) 5523-5526
19. Bold G., Fässler A., Capraro H.G., Cozens R., Klimkait T., Lazdins J., Mestan J., Poncioni B., Rösel J., Stover D., Tintelnot-Blomley M., Acemoglu F., Beck W., Boss E., Eschbach M., Hürlimann T., Masso E., Roussel S., Ucci-Stoll K., Wyss D., and Lang M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41 (1998) 3387-3401
20. Brabban D., Littlechild J., and Wisdom R. Stereospecific gamma-lactamase activity in a Pseudomonas fluorescens species. J. Ind. Microbiol. 16 (1996) 8-14
21. Branchadell V., Moreno-Mañas M., Pleixats R., Thorimbert S., Commandeur C., Boglio C., and Malacria M. The silicon effect on the regioselectivity of the Tsuji-Trost reaction. Experimental and theoretical approaches. J. Organom. Chem. 687 (2003) 337-345
22. Brown B., and Hegedus L.S. A novel, one-pot ring expansion of cyclobutanones Syntheses of carbovir and aristeromycin. J. Org. Chem. 65 (2000) 1865-1872
23. Cahn P. Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Exp. Opin. Investig. Drugs 13 (2004) 55-68
24. Caputo R., Guaragna A., Palumbo G., and Pedatella S. A new strategy for the asymmetric synthesis of 1,3-oxathiolane-based nucleoside analogues. Eur. J. Org. Chem. (1999) 1455-1458
25. Chapman H., Kernan M., Prisbe E., Rohloff J., Sparacino M., Terhorst T., and Yu R. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucl. Nucl. Nucl. Acids 20 (2001) 621-628
26. NAr) of fluorine. Tetrahedron Lett. 44 (2003) 1503-1506
27. Cheng J., Wang F., Xu J.-H., Pan Y., and Zhang Z. Palladium-catalyzed Suzuki-Miyaura reaction using aminophosphine as ligand. Tetrahedron Lett. 44 (2003) 7095-7098
28. Chevrin C., Le Bras J., Hénin F., and Muzart J. Water-mediated transition-metal-free Tsuji-Trost-type reaction. Tetrahedron Lett. 44 (2003) 8099-8102
29. Choudhury A., Moore J.R., Pierce M.E., Fortunak J.M., Valvis I., and Confalone P.N. In situ recycling of chiral ligand and surplus nucleophile for a noncatalytic reaction: amplification of process throughput in the asymmetric addition step of efavirenz (DMP 266). Org. Process Res. Dev. 7 (2003) 324-328
30. Coates, J.A., Mutton, I.M., Penn, C.R., Williamson, C., Storer, R., 2001. 1,3-Oxathiolane nucleoside analogues. US Patent 6,180,639.
31. Coppola, K., 2003. Process for the preparation of thiazole derivatives. US Patent 6,566,530.
32. Corbett A.H., Lim M.L., and Kashuba A.D. Kaletra (lopinavir/ritonavir). Ann. Pharmacother. 36 (2002) 1193-1203
33. Cousins R.P.C., Mahmoudian M., and Youds P.M. Enzymic resolution of oxathiolane intermediates-an alternative approach to the anti-viral agent Lamivudine (3TC™). Tetrahedron: Asymm. 6 (1995) 393-396
34. Crimmins M.T. New developments in the enantioselective synthesis of cyclopentyl carbocyelic nucleosides. Tetrahedron 54 (1998) 9229-9272
35. Crimmins M.T., and King B.W. An efficient asymmetric approach to carbocyclic nucleosides: asymmetric synthesis of 1592U89, a potent inhibitor of HIV reverse transcriptase. J. Org. Chem. 61 (1996) 4192-4193
36. Crimmins M.T., King B.W., Zuercher W.J., and Choy A.L. An efficient, general asymmetric synthesis of carbocyclic nucleosides: application of an asymmetric aldol/ring-closing metathesis strategy. J. Org. Chem. 65 (2000) 8499-8509
37. Daluge, S.M., 1991a. Therapeutic nucleosides. US Patent 5,034,394.
38. Daluge, S.M., 1991b. Therapeutics nucleosides. EP0434450 A2.
39. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir. Res. 38 (1998) 153-179
40. In: De Clercq E. (Ed). Antiretroviral Therapy (2001), American Society for Microbiology, Washington, DC, USA 359 pp.
41. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antivir. Res. 67 (2005) 56-75
42. De Clercq E. From adefovir to Atripla™ via tenofovir Viread™ and Truvada™. Future Virol. 1 (2006) 709-715
43. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6 (2007) 1001-1018
44. De Clercq E., and Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4 (2005) 928-940
45. Dionne, G., 1996. 1,3-Oxathiolane nucleoside compounds and compositions. US Patent 5,538,975.
46. Duschinsky, R., Heidelberger, C., 1960. 5-Fluorocytosine and preparation thereof. US Patent 2,945,038.
47. Evans B.E., Rittle K.E., Homnick C.F., Springer J.P., Hirshfield J., and Veber D.F. A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and gamma-(aminoalky1) gamma-lactones. J. Org. Chem. 50 (1985) 4615-4625
48. Evans C.T., Roberts S.M., Shoberu K.A., and Sutherland A.G. Potential use of carbocyclic nucleosides for the treatment of AIDS: chemo-enzymatic syntheses of the enantiomers of carbovir. J. Chem. Soc. Perkin Trans. 1 (1992) 589-592
49. Fan X., Song Y.-L., and Long Y.-Q. An efficient and practical synthesis of the HIV protease inhibitor atazanavir via a highly diastereoselective reduction approach. Org. Process Res. Dev. 12 (2008) 69-75
50. Fässler, A., Bold, G., Capraro, H. G., Steiner, H., 1997. Process for preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues. WO9746515.
51. Fässler A., Bold G., and Steiner H. A concise synthesis of aza-dipeptide isosteres. Tetrahedron Lett. 39 (1998) 4925-4928
52. Fässler, A., Bold, G., Capraro, H.G., Steiner, H., 1999. Intermediate for the preparation of peptide analogues. US Patent 5,912,352.
53. Fässler, A., Bold, G., Capraro, H.G., Lang, M., 2001. Azahexane derivatives as substrate isosteres of retroviral aspartate proteases. US Patent 6,225,345 B1.
54. Ferrero M., and Gotor V. Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides. Chem. Rev. 100 (2000) 4319-4347
55. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338 (1998) 1281-1292
56. Frantz D.E., Fässler R., and Carreira E.M. Facile enantioselective synthesis of propargylic alcohols by direct addition of terminal alkynes to aldehydes. J. Am. Chem. Soc. 122 (2000) 1806-1807
57. Frantz D.E., Fässler R., Tomooka C.S., and Carreira E.M. The discovery of novel reactivity in the development of C-C bond-forming reactions: in situ generation of zinc acetylides with Zn-(II)/R(3)N. Acc. Chem. Res. 33 (2000) 373-381
58. Fray A.H., Kaye R.L., and Kleinman E.F. A short, stereoselective synthesis of the lactone precursor to 2R,4S,5S hydroxyethylene dipeptide isosteres. J. Org. Chem. 51 (1986) 4828-4833
59. Frick L.W., John L.S., Taylor L.C., Painter G.R., Furman P.A., Liotta D.C., Furfine E.S., and Nelson D.J. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob. Agents Chemother. 37 (1993) 2285-22292
60. Genet J.P., and Savignac M. Recent developments of palladium(0) catalyzed reactions in aqueous medium. J. Organom. Chem. 576 (1999) 305-317
61. Ghosh A.K., and Fidanze S. Transition-state mimetics for HIV protease inhibitors: stereocontrolled synthesis of hydroxyethylene and hydroxyethylamine isosteres by ester-derived titanium enolate syn and anti-aldol reactions. J. Org. Chem. 63 (1998) 6146-6152
62. Ghosh A.K., McKee S.P., and Thompson W.J. An efficient synthesis of hydroxyethylene dipeptide isosteres: the core unit of potent HIV-1 protease inhibitors. J. Org. Chem. 56 (1991) 6500-6503
63. Ghosh A.K., McKee S.P., Thompson W.J., Darke P.L., and Zugay J.C. Potent HIV-1 protease inhibitors: stereoselective synthesis of a dipeptide mimic. J. Org. Chem. 58 (1993) 1025-1029
64. Ghosh A.K., Shin D., and Mathivanan P. Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir. Chem. Commun. (1999) 1025-1026
65. Giordano, C., Pozzoli, C., Benedetti, F., 2001. Process for the preparation of aryl-pyridinyl compounds. WO0127083 A1.
66. Gong Y.-F., Robinson B.S., Rose R.E., Deminie C., Spicer T.P., Stock D., Colonno R.J., and Lin P.-F. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44 (2000) 2319-2326
67. Goodyear, M.D., Dwyer, P.O., Hill, M.L., Whitehead, A.J., Hornby, R., Hallet, P., 1995. Process for the diastereoselective synthesis of nucleoside analogues. WO9529174.
68. Goodyear, M.D., Dwyer, P.O., Hill, M.L., Whitehead, A.J., Hornby, R., Hallet, P., 2000. Process for the diastereoselective synthesis of nucleoside analogues. US Patent 6,051,709.
69. Griffiths, G., Previdoli, F., 1993. Process for the production of 2-azabicyclo[2.2.1]hep-5-ene-3-one. US Patent 5,200,527.
70. Grim S.A., and Romanelli F. Tenofovir disoproxil fumarate. Ann. Pharmacother. 37 (2003) 849-859
71. In: Gutte B. (Ed). Peptides: Synthesis, Structures and Applications. (1995), Academic Press, San Diego
72. Haight A.R., Stuk T.L., Menzia J.A., and Robbins T.A. A convenient synthesis of enaminones using tandem acetonitrile condensation, grignard addition. Tetrahedron Lett. 38 (1997) 4191-4194
73. Haight A.R., Stuk T.L., Allen M.S., Bhagavatula L., Fitzgerald M., Hannick S.M., Kerdesky F.A.J., Menzia J.A., Parekh S.I., Robbins T.A., Scarpetti D., and Tien J.H.J. Reduction of an enaminone: synthesis of the diamino alcohol core of ritonavir. Org. Process Res. Dev. 3 (1999) 94-100
74. Hamashima Y., Sawada D., Kanai M., and Shibasaki M. A new bifunctional asymmetric catalysis: an efficient catalytic asymmetric cyanosilylation of aldehydes. J. Am. Chem. Soc. 121 (1999) 2641-2642
75. Hamashima Y., Sawada D., Nogami H., Kanai M., and Shibasaki M. Highly enantioselective cyanosilylation of aldehydes catalyzed by a Lewis acid-Lewis base bifunctional catalyst. Tetrahedron 57 (2001) 805-814
76. Heidelberger, C., Duschinsky, R., 1957. 5-Fluorouracil. US Patent 2,802,005.
77. Hodgson P.B., and Salingue F.H. The preparation of a stable 2-pyridylboronate and its reactivity in the Suzuki-Miyaura cross-coupling reaction. Tetrahedron Lett. 45 (2004) 685-687
78. Hodgson D.M., Witherington J., and Moloney B.A. Concise racemic and highly enantioselective approaches to key intermediates for the syntheses of carbocyclic nucleosides and pseudo-ribofuranoses: formal syntheses of carbovir. J. Chem. Soc. Perkin Trans. 1 (1994) 3373-3378
79. Holý A., and Rosenberg I. Preparation of 5′-O-phosphonylmethyl analogues of nucleoside-5′-phosphates 5′-diphosphates and 5'-triphosphates. Collect. Czech. Chem. Commun. 47 (1982) 3447-3463
80. Holý A., and Masojidkova M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases I. The stepwise approach. Collect. Czech. Chem. Commun. 60 (1995) 1196-1212
81. Holý A., Dvorakova H., and Masojidkova M. Synthesis of Enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases II. The synthon approach. Collect. Czech. Chem. Commun. 60 (1995) 1390-1409
82. Hutton C.A., and Skaff O. A convenient preparation of dityrosine via Miyaura borylation-Suzuki coupling of iodotyrosine derivatives. Tetrahedron Lett. 44 (2003) 4895-4898
83. Izawa K., and Onishi T. Industrial syntheses of the central core molecules of HIV protease inhibitors. Chem. Rev. 106 (2006) 2811-2827
84. Jeffery A.L., Kim J.-H., and Wiemer D.F. Synthesis of acyclic nucleoside and nucleotide analogues from amino acids: a convenient approach to a PMEA-PMPA hybrid. Tetrahedron 56 (2000) 5077-5083
85. Jin, L., Shi, X., Liu, B., 2004. Process for preparing alcohol by heterocyclic carboxylic ester reduction. Chinese Patent 1,554,648.
86. Jones J. The Chemical Synthesis of Peptides (1994), Oxford University Press, Oxford
87. Kabalka G.W., and Yao M.-L. Synthesis of a dicyclobutylideneethane derivative via sequential palladium-catalyzed Miyaura borylation and Suzuki coupling. Tetrahedron Lett. 44 (2003) 7885-7887
88. Kang S.H., and Ryu D.H. Versatile synthetic routes to threo-beta-amino hydroxy carboxylic acids, statine and its analogues. Bioorg. Med. Chem. Lett. 54 (1995) 2959-2962
89. Katagiri N., Takebayashi M., Kokufuda H., Kaneko C., Kanehira K., and Torihara M. Efficient synthesis of carbovir and its congener via π-allylpalladium complex formation by ring strain-assisted C-N bond cleavage. J. Org. Chem. 62 (1997) 1580-1581
90. Kempf D.J., Marsh K.C., Fino L.C., Bryant P., Craig-Kennard A., Sham H.L., Zhao C., Vasavanonda S., Kohlbrenner W.E., Wideburg N.E., Saldivar A., Green B.F., Herrin T., and Norbeck D.W. Design of orally bioavailable, symmetry-based inhibitors of HIV protease. Bioorg. Med. Chem. 2 (1994) 847-858
91. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.-P., Wideburg N.E., Saldivar A., Ruiz L., Kati W.M., Sham H.L., Robins T., Stewart K.D., Hsu A., Plattner J.J., Leonard J.M., and Norbeck D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2484-2588
92. Kempf, D.J., Norbeck, D.W., Sham, H.L., Zhao, C., 1996. Retroviral protease inhibiting compounds. US Patent 5,541,206.
93. Kempf D.J., Sham H.L., Marsh K.C., Flentge C.A., Betebenner D., Green B.E., McDonald E., Vasavanonda S., Saldivar A., Widebuurg N.E., Kati W.M., Ruiz L., Zhao C., Fino L.M., Patterson J., Molla A., Plattner J.J., and Norbeck D.W. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 41 (1998) 602-617
94. Kim C.U., Luh B.Y., Misco P.F., Bronson J.J., Hitchcock M.J.M., Ghazzouli I., and Martin J.C. Acyclic purine phosphonate analogs as antiviral agents. Synthesis and structure-activity relationships. J. Med. Chem. 33 (1990) 1207-1213
95. Kleemann A., and Engel J. Pharmaceutical Substances: Book and CD-ROM (1999), Thieme Publishing Group
96. Knöpfel T.F., Boyall D., and Carreira E.M. Diastereoselective zinc-catalyzed conjugate addition of alkynes. Org. Lett. 6 (2004) 2281-2283
97. Kotha S., Lahiri K., and Kashinath D. Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis. Tetrahedron 58 (2002) 9633-9695
98. Kraus, H., Fiege, H., 1998. Process for the preparation of 5-hydroxymethylthiazole. US Patent 5,780,638.
99. Laird T. Cost estimates for new molecules. Org. Process Res. Dev. 9 (2005) 125-126
100. Langridge, D.C., 1998. Process for the preparation of disubstituted carbonates. US Patent 5,773,625.
101. Leanna, M.R., 1996. Process for preparation of 5-hydroxymethylthiazole. World Patent WO9616050A1.
102. Leanna, M.R., Morton, H.E., Allen, M.S., 1998. Process for preparation of 5-hydroxymethylthiazole. US Patent 5,712,400.
103. Li Z.-B., and Pu L. BINOL-salen-catalyzed highly enantioselective alkyne additions to aromatic aldehydes. Org. Lett. 6 (2004) 1065-1068
104. Lloyd R.C., Lloyd M.C., Smith M.E.B., Holt K.E., Swift J.P., Keene P.A., Taylor S.J.C., and McCague R. Use of hydrolases for the synthesis of cyclic amino acids. Tetrahedron 60 (2004) 717-728
105. Luly J.R., Dellaria J.F., Plattner J.J., Soderquist J.L., and Yi N. A synthesis of protected aminoalkyl epoxides from alpha-amino acids. J. Org. Chem. 52 (1987) 1487-1492
106. MacKeith R.A., McCague R., Olivo H.F., Roberts S.M., Taylor S.J.C., and Xiong H. Enzyme-catalysed kinetic resolution of 4-endo-hydroxy-2-oxabicyclo[3,3.0]oct-7-en-3-one and employment of the pure enantiomers for the synthesis of anti-viral and hypocholestemic agents. Bioorg. Med. Chem. 2 (1994) 387-394
107. Menche D., Arikan F., Li J., and Rudolph S. Directed reductive amination of β-hydroxyketones: convergent assembly of the ritonavir/lopinavir core. Org. Lett. 9 (2007) 267-270
108. Milton J., Brand S., Jones M.F., and Rayner C.M. Enantioselective enzymatic synthesis of the anti-viral agent lamivudine (3TC™). Tetrahedron Lett. 36 (1995) 6961-6964
109. Murth, K.S.K., Horne, S.E., Reddy, G.V., Senanayake, C.B.W., Radatus, B.K., 2002. 1,3-Oxathiolan-5-ones useful in the production of antiviral nucleoside analogues. US Patent 6,380,388 B1.
110. Naesens L., Bischofberger N., Augustijns P., Annaert P., Van den Mooter G., Arimilli M.N., Kim C.U., and De Clercq E. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxy-carbonyloxy-methyl)-9-(2-phosphonylmethoxypropyl)-adenine in mice. Antimicrob. Agents Chemother. 42 (1998) 1568-1573
111. Nayek A., Banerjee S., Sinha S., and Ghosh S. Alkoxy group facilitated ring closing metathesis (RCM) of acyclic 1,6-dienes. Convenient synthesis of non-racemic highly substituted cyclopentenols. Tetrahedron Lett. 45 (2004) 6457-6460
112. Niwa S., and Soai K. Catalytic asymmetric synthesis of optically active alkynyl alcohols by enantioselective alkynylation of aldehydes and by enantioselective alkylation of alkynyl aldehydes. Chem. Soc. Perkin I (1990) 937-943
113. Nogami H., Matsunaga S., Kanai M., and Shibasaki M. Enantioselecitive strecker-type reaction promoted by polymer-supported bifunctional catalyst. Tetrahedron Lett. 42 (2001) 279-283
114. 3-adenergic receptor agonist. Chem. Pharm. Bull. 51 (2003) 702-709
115. 3 as catalyst reservoir. Lett. Org. Chem. 4 (2007) 13-15
116. Olivo H.F., and Yu J. Practical enantiodivergent syntheses of both enantiomers of carbovir 1592U89 and six-membered ring analogues. Chem. Soc. Perkin Trans. 1 (1998) 391-392
117. Painter G.R., Almond M.R., Mao S., and Liotta D.C. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 1035-1044
118. Pankiewicz K.W. Fluorinated nucleosides. Carbohydr. Res. 327 (2000) 87-105
119. Patel M., Ko S.S., McHugh Jr. R.J., Markwalder J.A., Srivastava A.S., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., and Seitz S.P. Synthesis and evaluation of analogs of efavirenz (SUSTIVA™) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 9 (1999) 2805-2810
120. Patel M., McHugh Jr. R.J., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., and Ko S.S. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors Analogs of efavirenz (SUSTIVA™). Bioorg. Med. Chem. Lett. 9 (1999) 3221-3224
121. Patel M., McHugh Jr. R.J., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., and Rodgers J.D. Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 10 (2000) 1729-1731
122. Peçanha E.P., Tanuri A., and Antunes O.A.C. Estratégias Farmacológicas para a Terapia Anti-AIDS. Química Nova 25 (2002) 1108-1116
123. Pierce M.E., Parsons Jr. R.L., Radesca L.A., Lo Y.S., Silverman S., Moore J.R., Islam Q., Choudhury A., Fortunak J.M.D., Nguyen D., Luo C., Morgan S.J., Davis W.P., Confalone P.N., Chen C., Tillyer R.D., Frey L., Tan L., Xu F., Zhao D., Thompson A.S., Corley E.G., Grabowski E.J.J., Reamer R., and Reider P.J. Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor. J. Org. Chem. 63 (1998) 8536-8543
124. Potuzak J.S., and Tan D.S. Synthesis of C1-alkyl- and acylglycals from glycals using a B-alkyl Suzuki-Miyaura cross coupling approach. Tetrahedron Lett. 45 (2004) 1797-1801
125. Radesca L.A., Lo Y.S., Moore J.R., and Pierce M.E. Synthesis of HIV-1 reverse transcriptase inhibitor DMP 266. Synth. Commun. 27 (1997) 4373-4384
126. Reeder M.R., and Anderson R.M. α-Aminoalkyl-α′-halomethylketones: preparation and application to pharmaceutically interesting compounds. Chem. Rev. 106 (2006) 2828-2842
127. Robbins B.L., Srinivas R.V., Kim C., Bischofberger N., and Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42 (1998) 612-617
128. Robins M.J., MacCoss M., Naik S.R., and Ramani G. Nucleic acid related compounds. 21. Direct fluorination of uracil and cytosine bases and nucleosides using trifluoromethyl hypofluorite. Mechanism, stereochemistry, and synthetic applications. J. Am. Chem. Soc. 98 (1976) 7381-7389
129. Robinson B.S., Riccardi K.A., Gong Y., Guo Q., Stock D.A., Blair W.S., Terry B.J., Deminie C.A., Djang F., Colonno R.J., and Lin P. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44 (2000) 2093-2099
130. Rodriguez-Barrios F., and Gago F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr. Top. Med. Chem. 4 (2004) 991-1007
131. Rouhi A.M. Simplifying syntheses is always a key goal. Chem. Eng. News 81 (2003) 41-43
132. Roulland E., Monneret C., and Florent J.-C. Enantioselective synthesis of the carbocyclic moiety of (-)-carbovir. Tetrahedron Lett. 44 (2003) 4125-4128
133. Saito S., Sakai M., and Miyaura N. A synthesis of biaryls via Nickel(0)-catalyzed cross-coupling reaction of chloroarenes with phenylboronic acids. Tetrahedron Lett. 37 (1996) 2993-2996
134. Saito S., Oh-tani S., and Miyaura N. Synthesis of biaryls via a Nickel(0)-catalyzed cross-coupling reaction of chloroarenes with arylboronic acids. J. Org. Chem. 62 (1997) 8024-8030
135. Sasaki H., Boyall D., and Carreira E.M. Facile asymmetric addition of acetylene to aldehydes: in situ generation of reactive zinc acetylide. Helv. Chim. Acta 84 (2001) 964-971
136. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.P., StClair M., Wilson J., Furman P.A., Painter G., Choi W.B., and Liotta D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36 (1992) 2423-2431
137. Schultze L.M., Chapman H.H., Dubree N.J.P., Jones R.J., Kent K.M., Lee T.T., Louie M.S., Postich M.J., Prisbe E.J., Rohloff J.C., and Yu R.H. Practical synthesis of the anti-HIV drug. PMPA. Tetrahedron Lett. 39 (1998) 1853-1856
138. Sham, H.L., Norbeck, D.W., Chen, X., Betebenner, D.A., 1999. Retroviral protease inhibiting compounds. US Patent 5,914,332.
139. Sham H.L., Betebenner D.A., Herrin T., Kumar G., Saldivar A., Vasavanonda S., Molla A., Kempf D.J., Plattner J.J., and Norbeck D.W. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (lopinavir). Bioorg. Med. Chem. Lett. 11 (2001) 1351-1353
140. Snieckus V. Directed ortho metalation Tertiary amide and O-carbamate directors in synthetic strategies for polysubstituted aromatics. Chem. Rev. 90 (1990) 879-933
141. Södergren M.J., Bertilsson S.K., and Anderson P.G. Allylic alcohols via catalytic asymmetric epoxide rearrangement. J. Am. Chem. Soc. 122 (2000) 6610-6618
142. Starrett Jr. J.E., Tortolani D.R., Russell J., Hitchcock M.J.M., Whiterock V., Martin J.C., and Mansuri M.M. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J. Med. Chem. 37 (1994) 1857-1864
143. Stolk L.M.L., and Lüers J.F.J. Increasing number of anti-HIV drugs but no definite cure-review of anti-HIV drugs. Pharm. World Sci. 26 (2004) 133-136
144. Stoner E.J., Stengel P.J., and Cooper A.J. Synthesis of ABT-378, an HIV protease inhibitor candidate: avoiding the use of carbodiimides in a difficult peptide coupling. Org. Process Res. Dev. 3 (1999) 145-148
145. Stuk T.L., Haight A.R., Scarpetti D., Allen M.S., Menzia J.A., Robbins T.A., Parekh S.I., Langridge D.G., Tien J.-H.J., Pariza R.J., and Kerdesky F.A.J. An efficient stereocontrolled strategy for the synthesis of hydroxyethylene dipeptide isosteres. J. Org. Chem. 59 (1994) 4040-4041
146. Tan L., Chen C., Tillyer R.D., Grabowski E.J.J., and Reider P.J. A novel, highly enantioselective ketone alkynylation reaction mediated by chiral zinc aminoalkoxides. Angew. Chem. Int. Ed. 38 (1999) 711-713
147. Tanaka M., Norimine Y., Fujita T., Suemune H., and Sakai K. Chemoenzymatic synthesis of antiviral carbocyclic nucleosides: asymmetric hydrolysis of meso-3,5-bis(acetoxymethyl)cyclopentenes using Rhizopus delemar lipase. J. Org. Chem. 61 (1996) 6952-6957
148. Thompson A.S., Corley E.G., Huntington M.F., and Grabowski E.J.J. Use of an ephedrine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone: asymmetric synthesis of the reverse transcriptase inhibitor L-743, 726. Tetrahedron Lett. 36 (1995) 8937-8940
149. Thompson A., Corley E.G., Huntington M.F., Grabowski E.J.J., Remenar J.F., and Collum D.B. Lithium ephedrate-mediated addition of a lithium acetylide to a ketone: solution structures and relative reactivities of mixed aggregates underlying the high enantioselectivities. J. Am. Chem. Soc. 120 (1998) 2028-2038
150. Thorimbert S., Taillier C., Bareyt S., Humilière D., and Malacria M. A stereoselective synthesis of silylated epoxycyclopentanols bearing four contiguous stereogenic centers. Tetrahedron Lett. 45 (2004) 9123-9126
151. Torque C., Bricout H., Hapiot F., and Monflier E. Substrate-selective aqueous organometallic catalysis. How size and chemical modification of cyclodextrin influence the substrate selectivity. Tetrahedron 60 (2004) 6487-6493
152. Trost B.M. Pd asymmetric alkylation (AAA) A powerful synthetic tool. Chem. Pharm. Bull. 50 (2002) 1-14
153. Trost B.M., Li L., and Guile S.D. A novel palladium-catalyzed cycloalkylation to isoxazoline 2-oxides. Application for the asymmetric synthesis of carbanucleosides. J. Am. Chem. Soc. 114 (1992) 8147-8745
154. Tsai C.C., Follis K.E., Sabo A., Beck T.W., Grant R.F., Bischofberger N., Benveniste R.E., and Black R. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270 (1995) 1197-1199
155. Vince R., and Hua M. Synthesis and anti-HIV activity of carbocyclic 2′,3′-didehydro-2′,3′-dideoxy 2,6-disubstituted purine nucleosides. J. Med. Chem. 33 (1990) 17-21
156. Wang P., Hong J.H., Cooperwood J.S., and Chu C.K. Recent advances in l-nucleosides: chemistry and biology. Antivir. Res. 40 (1998) 19-44
157. Wlodawer A., and Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998) 249-284
158. Xie Y., Hritzko B., Chin C.Y., and Wang N.-H.L. Separation of FTC-ester enantiomers using a simulated moving bed. Ind. Eng. Chem. Res. 42 (2003) 4055-4067
159. Xu Z., Singh J., Schwinden M.D., Zheng B., Kissick T.P., Patel B., Humora M.J., Quiroz F., Dong L., Hsieh D.-M., Heikes J.E., Pudipeddi M., Lindrud M.D., Srivastava S.K., Kronenthal D.R., and Mueller R.H. Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632. Org. Process Res. Dev. 6 (2002) 323-328
160. Young, S.D., Britcher, S.F., Payne, L.S., Tran, L.O., Lumma Jr., W.C., 1996. Benzoxazinones as inhibitors of HIV reverse transcriptase. US Patent 5,519,021.
161. Yu R.H., Schultze L.M., Rohloff J.C., Dudzinski P.W., and Kelly D.E. Process optimization in the synthesis of 9-[2-(diethylphosphonomethoxy)ethyl]adenine: replacement of sodium hydride with sodium tert-butoxide as the base for oxygen alkylation. Org. Process Res. Dev. 3 (1999) 53-55